Treatment patterns and economic burden of illness in patients with advanced bladder cancer receiving second-line therapy.

320Background: Second-line chemotherapies (SLCT) for bladder cancer (BC) are high in toxicity and yield low objective response rates resulting in low overall survival (OS). BC in general is an expensive malignancy to treat, but real-world SLCT treatment patterns and the associated burden of illness are absent from the published literature. The objective of this study was to describe chemotherapy regimens and evaluate the clinical and economic burdens of advanced BC in the second-line setting. Methods: Patients aged ≥18 years with newly diagnosed stage 3 or 4 BC (4/2011–9/2014) were identified from the Truven Health MarketScan Databases. Patients were continuously enrolled in health benefits 12 months before advanced diagnosis date through death, end of enrollment, or end of study period (12/2014) with no pre-diagnosis evidence of other primary cancers, HIV, or pregnancy. SLCT regimens, time on therapy, OS, and BC-specific resource use and costs were computed using the Kaplan-Meier sampling average method ...